Emergent BioSolutions：仍在等待持续执行的转型（NYSE:EBS）
· seekingalpha.com
Emergent BioSolutions面临利润率压力、FY26指引下调以及盈利能力薄弱，尽管进行了成本削减。在此了解EBS股票详情。
The big message we got from the Emergent BioSolutions Inc. ( EBS ) call is that whilst they're making some tangible progress on the balance sheet and cost struc...